EMA issues positive scientific opinion on early treatment of Covid-19

GlaxoSmithKline (GSK) and Vir Biotechnology have announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. This relates to the use of sotrovimab for the treatment of adults and adolescents aged over 12 years with Covid-19 who do not require oxygen supplementation and who are at risk of progressing to severe Covid-19.

The CHMP opinion can now be considered by the national authorities in EU member states when taking evidence-based decisions on the early use of the medicine prior to marketing authorisation.

Christopher Corsico, Senior Vice President, Development, GSK, said: “As the Covid-19 pandemic continues and the virus generates new variants of concern, including those that recently emerged in India, the need for therapies that can slow the progression of disease in patients who are at high risk for developing severe complications remains a top priority. Monoclonal antibody treatments are a critical part of a comprehensive solution to Covid-19, especially as less than 40% of adults across EU member states have received at least one dose of a vaccine to date. We are encouraged by this positive scientific opinion from the EMA, as it hopefully brings us closer to making sotrovimab available for patients across Europe.”

George Scangos, CEO of Vir, said: “Today’s opinion is great news for patients across Europe, as EU member states are now more easily able to move forward with their own temporary authorisations for sotrovimab. Based on our most recent in vitro data, sotrovimab continues to combat Covid-19 as it evolves and has retained activity against all circulating variants of concern. We look forward to continuing to work with regulators around the world to make sotrovimab available to more patients in need and help bring an end to the pandemic.”

The CHMP reached its opinion following a review of data including an interim analysis of efficacy and safety data from the Phase III COMET-ICE (Covid-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated sotrovimab as monotherapy for the early treatment of Covid-19 in adults at high risk of hospitalisation. Efficacy results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85% (p=0.002) reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial. As a result, the Independent Data Monitoring Committee recommended that the trial be stopped for enrolment due to evidence of profound efficacy. The CHMP also considered data on the medicine’s quality and safety.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free